Johnson & Johnson temporarily halts Covid-19 vaccine output: report
NYSE - LSE
| RBGPF | 1.47% | 68 | $ | |
| CMSC | 0.08% | 22.4799 | $ | |
| JRI | 0.54% | 12.94 | $ | |
| SCS | 1.03% | 11.215 | $ | |
| BCE | 0.73% | 23.14 | $ | |
| RIO | -2.69% | 59.43 | $ | |
| BCC | -0.22% | 98.085 | $ | |
| CMSD | -0.05% | 22.699 | $ | |
| NGG | -0.26% | 65.4 | $ | |
| RYCEF | -2.16% | 9.7 | $ | |
| RELX | -0.14% | 50.09 | $ | |
| GSK | -1.27% | 38.255 | $ | |
| AZN | -1.45% | 72.735 | $ | |
| BTI | 1.52% | 41.135 | $ | |
| BP | -0.13% | 33.815 | $ | |
| VOD | -0.59% | 9.395 | $ |
Johnson & Johnson temporarily halts Covid-19 vaccine output: report
Johnson & Johnson has temporarily suspended production at a key plant manufacturing the Covid-19 vaccine, the New York Times reported Tuesday.
The facility in the Dutch city of Leiden halted output late last year, according to the report, which cited people familiar with the decision.
J&J, without confirming or denying the report, said it has continued to fulfill delivery commitments, a company spokesman said.
The factory, which is currently making an experimental vaccine, is expected to resume production of the Covid-19 vaccine again in a "few" months, the Times reported.
J&J currently has "millions of doses of our Covid-19 vaccine in inventory," according to the J&J spokesman.
"We continue to fulfill our contractual obligations in relation to the Covax facility and the African Union," the company spokesman said.
J&J has projected sales of $3 billion to $3.5 billion in 2022 for its Covid-19 vaccine, much less than the $32 billion forecast by Pfizer for the same period.
But the J&J vaccine has been sought after in developing countries because, unlike other options, it does not require transportation at very cold temperatures. Also, the vaccine was originally billed as a single-shot inoculation.
Additional plants are being outfitted to make the vaccine, but production is not expected until late spring, the Times said.
L.Bohannon--NG
